XML 50 R52.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Schedule of Net Income (Loss) Per Ordinary Share) (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 12 Months Ended
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Numerator:                      
Income from continuing operations                 $ 57,326us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest $ 216,312us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest $ 261,149us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
Loss from continuing operations attributable to noncontrolling interests, net of tax                 (1,061)us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity 0us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity 0us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
Income from continuing operations attributable to Jazz Pharmaceuticals plc                 58,387jazz_NetIncomeLossAttributableToParentBeforeDiscontinuedOperations 216,312jazz_NetIncomeLossAttributableToParentBeforeDiscontinuedOperations 261,149jazz_NetIncomeLossAttributableToParentBeforeDiscontinuedOperations
Income from discontinued operations                 0us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity 0us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity 27,437us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
Net income attributable to Jazz Pharmaceuticals plc $ 81,612us-gaap_NetIncomeLoss $ 25,766us-gaap_NetIncomeLoss $ 43,659us-gaap_NetIncomeLoss $ (92,650)us-gaap_NetIncomeLoss $ 55,293us-gaap_NetIncomeLoss $ 75,409us-gaap_NetIncomeLoss $ 42,185us-gaap_NetIncomeLoss $ 43,425us-gaap_NetIncomeLoss $ 58,387us-gaap_NetIncomeLoss $ 216,312us-gaap_NetIncomeLoss $ 288,586us-gaap_NetIncomeLoss
Denominator:                      
Weighted-average ordinary shares used in calculating net income per ordinary share attributable to Jazz Pharmaceuticals plc - basic (in shares)                 59,746us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 58,298us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 56,643us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
Dilutive effect of employee equity incentive and purchase plans (in shares)                 2,402us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements 1,772us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements 1,536us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
Dilutive effect of warrants (in shares)                 466us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants 1,499us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants 2,016us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants
Weighted-average ordinary shares used in calculating net income per ordinary share attributable to Jazz Pharmaceuticals plc - diluted (in shares)                 62,614us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 61,569us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 60,195us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
Basic:                      
Income from continuing operations (in dollars per share)                 $ 0.98us-gaap_IncomeLossFromContinuingOperationsPerBasicShare $ 3.71us-gaap_IncomeLossFromContinuingOperationsPerBasicShare $ 4.61us-gaap_IncomeLossFromContinuingOperationsPerBasicShare
Income from discontinued operations (in dollars per share)                 $ 0.00us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare $ 0.00us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare $ 0.48us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
Net income (in dollars per share) $ 1.35us-gaap_EarningsPerShareBasic $ 0.43us-gaap_EarningsPerShareBasic $ 0.73us-gaap_EarningsPerShareBasic $ (1.58)us-gaap_EarningsPerShareBasic $ 0.96us-gaap_EarningsPerShareBasic $ 1.30us-gaap_EarningsPerShareBasic $ 0.72us-gaap_EarningsPerShareBasic $ 0.74us-gaap_EarningsPerShareBasic $ 0.98us-gaap_EarningsPerShareBasic $ 3.71us-gaap_EarningsPerShareBasic $ 5.09us-gaap_EarningsPerShareBasic
Diluted:                      
Income from continuing operations (in dollars per share)                 $ 0.93us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare $ 3.51us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare $ 4.34us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare
Income from discontinued operations (in dollars per share)                 $ 0.00us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare $ 0.00us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare $ 0.45us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
Net income (in dollars per share) $ 1.30us-gaap_EarningsPerShareDiluted $ 0.41us-gaap_EarningsPerShareDiluted $ 0.70us-gaap_EarningsPerShareDiluted $ (1.58)us-gaap_EarningsPerShareDiluted $ 0.90us-gaap_EarningsPerShareDiluted $ 1.23us-gaap_EarningsPerShareDiluted $ 0.69us-gaap_EarningsPerShareDiluted $ 0.71us-gaap_EarningsPerShareDiluted $ 0.93us-gaap_EarningsPerShareDiluted $ 3.51us-gaap_EarningsPerShareDiluted $ 4.79us-gaap_EarningsPerShareDiluted